Corvida™ is in development to be a best-in-class, orally administered drug for the treatment of NAFLD and NASH (Stages F2 through F3) with no worsening of Fibrosis in patients with or without Type 2 Diabetes.
Between 30% - 40% of adults in the US have NAFLD. About 3% - 5% of adults suffer from NASH, a progressive form of NAFLD that can lead to cardiovascular disease, cirrhosis and liver-related mortality. Approximately 45% - 75% of people with Type 2 Diabetes have NAFLD or NASH.
